After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

In today's healthcare landscape, there is a pressing need for quantitative methodologies that include the patients' ...

UK Prime Minister Sir Keir Starmer is due to reveal the long-awaited 10 Year Plan for the NHS later today, but revealed some ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced ...

The UK’s regulator, the MHRA, will be running five pilot dialogues as part of its first year exploring a real-world evidence ...

For AI to be transformative in the pharmaceutical industry, it must be designed with a security-first approach. This means ...

The transition from writing to programming regulatory submissions represents one of the most significant efficiency ...

Finding a conversation about AI at a conference like BIO 2025 is easy. But making those conversations meaningful and asking ...

Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another ...